

## BGF World Healthscience Fund Class A2 USD

## AUGUST 2021 FACTSHEET

Performance, Portfolio Breakdowns, Net Assets as at: 31/08/2021. All other data as at 08/09/2021.

For Investors in Belgium. Investors should read the Key Investor Information Document and Prospectus prior to investing.

## FUND OVERVIEW

This fund is a compartment of Luxembourg SICAV BlackRock Global Funds

The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund's assets. The Fund invests globally at least 70% of its total assets in the equity securities (e.g. shares) of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. The investment adviser (IA) may use financial derivative instruments (FDIs) (i.e. investments the prices of which are based on one or more underlying assets) for investment purposes in order to achieve the investment objective of the Fund, and/or to reduce risk within the Fund's portfolio, reduce investment costs and generate additional income. The Fund may, via FDIs, generate varying amounts of market leverage (i.e. where the Fund gains market exposure in excess of the value of its assets). The IA has discretion to select the Fund's investments and in doing so may take into consideration the MSCI World Healthcare Index. Recommendation: This Fund may not be appropriate for short-term investment. Your shares will be non-distributing (i.e. dividend income will be included in their value). Your shares will be denominated in US Dollar, the Fund's base currency. You can buy and sell your shares daily. The minimum initial investment for this share class is US\$5,000 or currency equivalent. The investment objective is an integral copy of the investment policy included in the KIID.

## EVOLUTION OF THE NAV X 1,000 SINCE INCEPTION



Share Class and Benchmark Net Asset Value (NAV) evolution x 1,000 displayed in USD. The figures shown relate to past performance. Past performance is not a reliable indicator of future results and should not be the sole factor of consideration when selecting a product or strategy. In the past, the return of your investment has been negatively or positively impacted by currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: BlackRock. NAV is published on www.fundinfo.com

## 12 MONTH PERIODS PERFORMANCE - ANNUALISED (%)

	30/6/2016- 30/6/2017	30/6/2017- 30/6/2018	30/6/2018- 30/6/2019	30/6/2019- 30/6/2020	30/6/2020- 30/6/2021	2020 Calendar Year
Share Class	13,10%	7,45%	11,22%	14,33%	22,54%	13,99%

The figures shown relate to past performance. Past performance is not a reliable indicator of future results and should not be the sole factor of consideration when selecting a product or strategy. Share Class and Benchmark performance displayed in USD, hedged fund benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, net of fees with gross income reinvested where applicable. In the past, the return of your investment has been negatively or positively impacted by currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: BlackRock

## CUMULATIVE &amp; ANNUALISED PERFORMANCE

Share Class	Cumulative (%)					Annualised (% p.a.)		
	1m	3m	6m	YTD	1 Year	3 Year	5 Year	Since Inception
Share Class	1,70%	6,09%	13,75%	12,75%	18,40%	14,21%	14,00%	9,72%

**Capital at risk.** All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.

## SYNTHETIC RISK &amp; REWARD INDICATOR (SRRI)



## KEY FACTS

Asset Class	Equity
Morningstar Category	Sector Equity Healthcare
Fund Launch Date	06/04/2001
Share Class Launch Date	06/04/2001
Fund Base Currency	USD
Share Class Currency	USD
Total Fund Size (M)	14.078,12 USD
Domicile	Luxembourg
Fund Type	Compartment of Luxembourg SICAV
ISIN	LU0122379950
Bloomberg Ticker	MEALU LX
Distribution Type	None
Minimum Initial Investment	5.000 USD*

\* or currency equivalent

## PORTFOLIO MANAGER(S)

Erin Xie  
Jeff Lee  
Xiang Liu

## TOP HOLDINGS (%)

ABBOTT LABORATORIES	5,33
UNITEDHEALTH GROUP INC	5,30
PFIZER INC	5,15
JOHNSON & JOHNSON	4,74
THERMO FISHER SCIENTIFIC INC	4,73
ELI LILLY	4,21
ROCHE HOLDING PAR AG	3,75
SANOFI SA	3,08
MEDTRONIC PLC	2,39
BOSTON SCIENTIFIC CORP	2,31
<b>Total of Portfolio</b>	<b>40,99</b>

Holdings subject to change

## RATINGS\*

FOR MORE INFORMATION ON MORNINGSTAR'S RATINGS, PLEASE VISIT: [HTTP://WWW.MORNINGSTAR.BE/BE/HELP/METHODOLOGY.ASPX](http://WWW.MORNINGSTAR.BE/BE/HELP/METHODOLOGY.ASPX).



## CUMULATIVE & ANNUALISED PERFORMANCE

**The figures shown relate to past performance. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.**

Share Class and Benchmark performance displayed in USD, hedged fund benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, net of fees with gross income reinvested where applicable. In the past, the return of your investment has been negatively or positively impacted by currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. **Source:** BlackRock

**Key Risks:** Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political or regulatory events. The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events. Active management of currency exposure through derivatives make the Fund sensitive to changes in foreign exchange rates. If the currency exposures against which the Fund is hedged appreciates investors may not benefit from such appreciation. Counterparty Risk: The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss.

## SECTOR BREAKDOWN (%)

	Fund
Pharmaceuticals	35,46
Health Care Equip. & Supplies	23,84
Biotechnology	15,29
Health Care Providers & Services	13,47
Life Sciences Tools & Services	8,67
Cash and/or Derivatives	2,64
Capital Markets	0,32
Health Care Technology	0,31

Negative weightings may result from specific circumstances (including timing differences between trade and settlement dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management. Allocations are subject to change.

## FEES AND CHARGES

<b>Max Initial Charge</b>	5,00%
<b>Exit Fee</b>	0,00%
<b>Ongoing Charge</b>	1,81%
<b>Performance Fee</b>	0,00%


The tax on stock exchange transactions associated with exit from and conversion of collective investment scheme units (accumulating shares) is 1.32% (max. EUR 4,000). Dividends received from distributing shares are subject to the Belgian withholding tax of 30%. The Belgian withholding tax applicable to interests included in the repurchase price of accumulating and distributing shares investing more than 10% of their assets in any kind of debts amounts to 30%.

## DEALING INFORMATION


<b>Settlement</b>	Trade Date + 3 days
<b>Dealing Frequency</b>	Daily, forward pricing basis
<b>Dilution</b>	Max 1.5%

You should read the prospectus and KIID before making any investment decision. They can be found at <http://kiid.blackrock.com>. For any complaint about this fund, please contact BlackRock on +32 2402-4903 or by email at [belux@blackrock.com](mailto:belux@blackrock.com). You can also contact the Consumer Mediation Service. More information can be found at <http://www.ombudsfm.be>. Visit [www.fundinfo.com](http://www.fundinfo.com) or our website [www.blackrock.com/be](http://www.blackrock.com/be) for the publication of the net asset value. Subscriptions for BGF collective investment scheme compartments will be accepted exclusively on the basis of the current prospectus, the KIID and the most recent annual report published by SICAV BlackRock Global Funds. Copies of these documents are available free of charge in English and if available in French or in Dutch (for the KIID) from the offices of our trading partners (distributors) and from BlackRock financial services in Belgium: J.P. Morgan Chase Bank, Boulevard du Roi Albert II 1, B-1210 Brussels. Copies of these documents are also available free of charge from the Belgian office of BlackRock Investment Management (UK) Limited, Square de Meeûs 35, B-1000 Brussels.

## GEOGRAPHIC BREAKDOWN (%)



## MARKET CAPITALISATION (%)



 02 402 49 00

 [belux@blackrock.com](mailto:belux@blackrock.com)

 [www.blackrock.com/be](http://www.blackrock.com/be)

## IMPORTANT INFORMATION:

All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed. BlackRock Global Funds (BGF) is an open-ended investment company established in Luxembourg which is available for sale in certain jurisdictions only. This company has the status of a collective investment scheme investing in securities (Dutch acronym: ICBE) and its separate compartments are suitable for selling in Belgium. Investment in BGF is exclusively open to investors who are neither citizens nor residents of the United States. The fund does not have a determined duration period. The minimum initial investment for this share class is shown under the 'Key Facts' section on page 1. There is an initial charge of up to 5% of the price of the Class A Shares and Class D Shares issued, where levied. The maximum entry charges to be paid by the private investor (class A shares). For further information, please refer to the KIID. Please read the section entitled 'Special risk considerations' in the prospectus for more information. Price fluctuations can be particularly large in the case of a fund with high volatility and the value of an investment can suddenly fall substantially. Currency movements can also cause the value of the investments to rise and fall. You may not get back the original amount of your investment. BGF is not available for sale in the U.S. or to U.S. persons. Product information concerning BGF should not be published in the U.S. Subscriptions in BGF are valid only if made on the basis of the current Prospectus, the most recent financial reports and the Key Investor Information Document, which are available on our website. Prospectuses, Key Investor Information Documents and application forms may not be available to investors in certain jurisdictions where the Fund in question has not been authorised. Issued by BlackRock Investment Management (UK) Limited (authorised and regulated by the Financial Conduct Authority). Registered office: 12 Throgmorton Avenue, London, EC2N 2DL. Registered in England No. 2020394. Tel: 020 7743 3000. For your protection, telephone calls are usually recorded. BlackRock is a trading name of BlackRock Investment Management (UK) Limited. When this document is issued in the EEA, it is issued by BlackRock (Netherlands) BV: Amstelplein 1, 1096 HA, Amsterdam, Tel: 020 – 549 5200, Trade Register No. 17068311. For more information, please see the website: [www.blackrock.com](http://www.blackrock.com). For your protection telephone calls are usually recorded. BlackRock is a trading name of BlackRock (Netherlands) B.V.. © 2021 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, iSHARES, SO WHAT DO I DO WITH MY MONEY, INVESTING FOR A NEW WORLD, and BUILT FOR THESE TIMES are registered and unregistered trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners.

**BLACKROCK®**

## GLOSSARY

**Market Capitalisation:** is the total value of the shares issued by a company which trades on the stock exchange.

**Ongoing Charge:** is a figure representing all annual charges and other payments taken from the fund.

**Price to Book Ratio:** represents the ratio of the current closing price of the share to the latest quarter's book value per share.

**Price to Earnings (TTM) Ratio:** represents the ratio of the market price per share of a company to the company's earnings per share for a twelve-month period (usually the last 12 months or trailing twelve months (TTM)).

**SRRI:** is a value based on the volatility of the fund, which gives an indication of the overall risk and reward profile of the Fund.

**Performance Fee:** is charged on any returns that, subject to a High Water Mark, the Fund achieves above its performance fee benchmark. Please refer to the Prospectus for further information.

**Dilution:** The Net Asset Value of the relevant Fund may be adjusted by an amount (not exceeding 1.50%, or 3% of that Net Asset Value in the case of fixed income Funds) which reflects the dealing costs and the estimated bid/offer spread of the respective assets.